

# Detection of OXA-23, OXA-48, OmpA and bla-TEM genes in carbapenem-resistance *Acinetobacter baumannii* and Biofilm formation in burn patients at Al-Anbar Government

*By Noor Nadhom Khalaf*

TYPE OF ARTICLE: Original Article

## Detection of OXA-23, OXA-48, OmpA and bla-TEM genes in carbapenem-resistance *Acinetobacter baumannii* and Biofilm formation in burn patients at Al-Anbar Government

Noor Nadhom Khalaf <sup>1\*</sup>, Shaymaa Hafez Maiteb<sup>2</sup>, Mohammed Jasim Mohammed<sup>3</sup>

- <sup>1\*</sup> University of Anbar, College of Medicine, Department of Microbiology, Iraq  
<sup>2</sup> PhD in Medical Microbiology /University of Anbar, College of Pharmacy, Iraq  
<sup>3</sup> FIBMS, University of Anbar, College of Medicine, Department of Surgery, Iraq

corresponding author: Noor Nadhom Khalaf  
Email: [noo22m0003@uoanbar.edu.iq](mailto:noo22m0003@uoanbar.edu.iq)

### ABSTRACT

**Background.** Antibiotic-resistant bacteria represent a highly global health issue by causing high rates of morbidity and mortality in burn units, whereas biofilms significantly contribute to complications in burn patients.

**Objectives.** The study investigates the prevalence of (OXA-23, OXA-48, OmpA and bla-TEM) and biofilm formation of *Acinetobacter baumannii* in the Burn Unit of the Al-Anbar government.

**Methods.** A total of 120 clinical swab samples from burn patient were collected from December 2023 to April 2024 from the burn units of Ramadi Teaching Hospital and Falluja Teaching Hospital for the study. The colonies were identified using conventional and Vitek methods. Colourimetric technique (MTP) and multiplex PCR were used to detect biofilms and resistance genes.

**Results.** Among 120 samples, 40 (33.3%) were *Acinetobacter baumannii*, 34 (80%) were MDR-resistant, and 6 (15%) were XDR. 90% of the isolates were resistant to Cefotaxime and Colisitin was more sensitive in all forty isolates. All 40 isolates formed significant biofilms. The percentage of positive results for OXA-23, OmpA and bla-TEM genes were 80%, 65%, and 55% of respectively. Carbapenem testing is essential to identify carbapenem-producing strains from non-producing

44 strains due to the high prevalence of multidrug-resistant *A.baumannii* with the OXA-23 and OmpA genes.

21 **Conclusion.** These findings highlight the urgent need for effective infection control measures and the development of new therapeutic strategies to manage these infections in burn patients.

33 **Keywords:** Burn, Biofilm formation, Multidrug-resistant (MDR), OXA-23, Colistin, *Acinetobacter baumannii*

## INTRODUCTION

*Acinetobacter baumannii* is a frequent source of hospital-acquired infections in patients with burns. It is a significant opportunistic pathogen responsible for increasing mortality and morbidity rates in poor nations [1]. *A.baumannii* is ranked at the highest level on the WHO priority pathogen list, being classified as "critical." This signifies the significant importance of this hospital-acquired infection, mainly when it exhibits resistance to carbapenem, considered the final line of defense antibiotic [2]. Significant mortality has been attributed to infections induced by extensively drug-resistant (XDR) and multidrug-resistant (MDR) strains of *A.baumannii*. Furthermore, a considerable number of outbreaks have been documented on a global scale [3].

Acinetobacter can thrive under inhospitable conditions such as desiccation, antimicrobial treatments, and limited nutrition supply. The resistance mechanism is comparable to that of other Gram-negative bacteria. This process entails the utilization of hydrolyzing enzymes or modifying enzymes, efflux pumps for the expulsion of antibiotics, and less penetration of antibiotics. *A.baumannii* is characterized by its many pumps and diverse enzymes [4]. Resistant to carbapenem antibiotics. *A. baumannii* is commonly reported worldwide, with a significant prevalence of carbapenem-resistant strains in developing nations such as Korea, Pakistan, India, Chile, and Portugal, as opposed to developed countries [5].

56 *Acinetobacter baumannii* is characterized by its ability to produce biofilms, which is a significant mechanism of pathogenicity. Physicochemical parameters like as oxygen level, temperature, growing medium, surface hydrophobicity, and pH have an impact on several microbe features, including resistance genes, adhesins, capsular polysaccharides, surface appendages, and virulence genes [6]. Infections caused by *A.baumannii* can pose a significant treatment challenge

when they form a biofilm and can spread rapidly across patients, leading to difficult-to-control outbreaks. A wide variety of hospital and medical device surfaces are ideal for biofilm formation. This includes endotracheal tubes made of polystyrene, polypropylene, polytetrafluoroethylene, and glass, heart valves, prosthetic joints, ventilators, and intravascular or urinary catheters [7]. Carbapenem-inactivating enzymes, including the Class D carbapenemase (OXA enzymes), are the primary cause of resistance in *A. baumannii* globally [8]. Based on the multifactorial nature of biofilm development, various gene products, including Omp of *A. baumannii*, have been identified as significant contributors to adhesiveness and biofilm formation in *A. baumannii* [9]. The blaTEM genes also have been widely acknowledged as the most abundant genes that confer antibiotic resistance in pathogenic bacteria worldwide [10]. Apart from its capacity to generate biofilms, *Acinetobacter*'s adeptness in acquiring and transmitting antibiotic-resistance genes confers an additional competitive edge in healthcare settings, where antibiotic utilization is consistently more significant than in other environments. Research has demonstrated that genes responsible for resistance to metals, carbapenemases, oxacillinases, metallo-beta-lactamases, and antibiotics can be horizontally transferred through different mechanisms, including outer membrane vesicles, conjugation, transformation, transfer mediated by bacteriophages, transfer mediated by nanotubes, and outer membrane transfer [11].

## MATERIAL AND METHODS

### Data sources

A total of 120 clinical samples from burn patients were collected from December 2023 to April 2024 from the burn units of Ramadi Teaching Hospital and Falluja Teaching Hospital for the study.

### Specimens

Swab Samples are collected from different body parts using a sterile transport medium swab and then cultured on selective media (24 h at 37 °C) following bacteriology standards. Exclusion includes immunocompromised patients like diabetic patients, chemotherapy, pregnant women, etc.

### *Acinetobacter* species identification.

Microscopic examination was performed on all samples, excluding blood, using Gram-stained smears. The samples were inoculated onto suitable culture media and incubated, and growth was

detected using standard microbiological techniques after the recommended length. <sup>1</sup> Smooth, opaque colonies observed on blood agar, which matched the non-lactose fermenting colonies on MacConkey, were identified as Acinetobacter and subjected to additional analysis. The identification of species within the Acinetobacter genus was conducted using various biochemical assays, including <sup>10</sup> triple sugar iron (TSI) fermentation test, oxidase, indole, motility, urease, and arginine hydrolysis [12], and by Vitek2 system (bioMérieux).

### <sup>27</sup> Antibiotic susceptibility test

The antibiotic susceptibility test of bacterial isolates is conducted using Kirby Bauer's Disc Diffusion method. <sup>61</sup> 0.5 McFarland concentration of A.baumannii isolates were cultured on Mueller-Hinton Agar(24 h at 37 °C) [13]. 10-14 different antibiotics were used. These antibiotics include cell wall inhibitors such as Piperacillin-tazobactam, Cefepime, Aztreonam, Ceftazidime, Amoxicillin-clavulanic acid, and Imipenem.

Additionally, cell membrane inhibitors like Colistin sulfate and polymyxin-B are used, along with a protein synthesis inhibitor called Amikacin and a DNA replication inhibitor known as Ciprofloxacin. Results are interpreted according to the guidelines of CLSI-2023. Vitek2 system (bioMérieux) is also used for antibiotic susceptibility tests for Acinetobacter baumannii isolates (Figure 1).

### <sup>69</sup> Detection of multidrug-resistant bacteria

<sup>3</sup> A recently published document by the Centers for Disease Control and Prevention (CDC) offers a precise definition of multidrug-resistant (MDR) isolates: their transformation from one or more antibiotics in three or more antibiotic categories to resistance. This definition is recognized internationally. XDR is defined as the ability of bacterial isolates to withstand at least one agent from all antimicrobial categories, with the exception of two or fewer. This means that they are susceptible to only one or two categories.

### Biofilm Formation Quantitative Assay

Biofilm formation is quantified using a colorimetric microtiter technique (Spectrophotometric method) [14]. The assay involved the following steps:



1. A bacterial suspension was adjusted to a turbidity of 0.5 McFarland in Brain Heart Infusion (BHI) broth with 1% glucose, achieving a concentration of 1.108 CFU/mL.
2. The suspension was diluted to 5.106 CFU/mL (1/20 dilution) and further to 5.105 CFU/mL (1/10 dilution) by mixing 180  $\mu\text{L}$  of BHI with glucose and 20  $\mu\text{L}$  of the bacterial suspension in a sterile 96-well polystyrene microplate.
3. The microplates were incubated at 37°C for 24 hours to allow biofilm formation.
4. After incubation, wells were washed twice with phosphate-buffered saline (PBS) to remove non-adherent cells.
5. Adherent biofilms were stained with 100  $\mu\text{L}$  of 0.1% crystal violet for 15 minutes.
6. Wells were washed twice with PBS to remove excess stains.
7. The crystal violet-stained biofilms were dissolved with 150  $\mu\text{L}$  of 95% ethanol, and the absorbance was measured at 570 nm using a microplate reader.

The optical density cutoff value (ODc) was used to categorize isolates as biofilm producers or non-producers.

## Molecular Analysis

### DNA extraction

The DNA extractions from all samples of pathogenic *Acinetobacter* were conducted using the Bosphore extraction versatile Spin Kit (Anatolia genworks-Istanbul, Turkiye), following the manufacturer's instructions. The liquid portion containing DNA was used as a template for multiplex polymerase chain reaction (mPCR). The DNA quality was assessed by quantifying the A260/A280 ratio using an ultraviolet spectrophotometer and determining its integrity using agarose electrophoresis. The genomic DNA (gDNA) of the strains mentioned above was preserved at a temperature of -40 °C until it was defrosted on ice just before analysis.

### DNA Amplification and Detection

The method of multiplex PCR was employed to detect the presence of the following resistance genes, namely carbapenem resistance OXA-23, OXA-48, OmpA and bla-TEM, as described in earlier studies. The primers, temperature and cycling settings utilized were as follows: for the bla-TEM gene (forward primer: 5'GAGACAATAACCCTGGTAAAT-3', reverse primer:

5'AGAAGTAAGTTGGCAGCAGTG-3') [15], OXA-23 (forward primer: 5'-GATCGGATTGGAGAACCAGA-3', reverse primer: 5'ATTCTGACCGCATTTCAT-3')(3), and OXA-48 (forward primer: 5'GCGTGTTAAGGATGAACAC-3', reverse primer: 5'-CATCAAGTTCAACCCAACCG-3') [16]. (forward primer: 5' -ATCGAATTCGCTACTATGCTTGTGCTGCT -3', reverse primer: 5'-ATGTAAGCTTCGCTTCTTGACCAGGTTGAAC -3') for OmpA gene [17]. The amplification condition for bla-TEM and AbOmpA involved an initial denaturation at 94°C for 5 minutes, followed by 35 cycles of 95°C for 1 minute, 56°C for 45 seconds, and 72°C for 1 minute. The amplification was concluded with a final extension at 72°C for 7 minutes. For OXA-23 and OXA-48 the process begins with an initial denaturation at a temperature of 94°C for 5 minutes. This is followed by 35 cycles, each consisting of a denaturation step at 94°C for 30 seconds, an annealing step at 56°C for 45 seconds, and an extension step at 72°C for 1 minute. An initial denaturation at 94°C for 5 minutes, followed by 35 cycles of 94°C for 1 minute, 60.9°C for 45 seconds, and 72°C for 1 minute, final extension at 72°C for 7 minutes the condition of AbOmpA Gene. To detect amplified genes, 10 µL of each reaction was analyzed using gel electrophoresis on a 2% agarose gel that included ethidium bromide (5 µg/mL). The gel was exposed to an electric field of 100 V for 1 hour in a buffer solution with a concentration of 0.5 × TBE. The amplified DNA bands were then seen using a UV transilluminator. The size of the blaTEM amplicon was 459 base pairs (bp), size of OmpA was 1043bp, the size of the OXA-23 amplicon was 501 bp, and the size of the OXA-48 amplicon was 438 bp.

### Analysis of statistical data

The data analysis was conducted using the IBM SPSS-29 statistical tool (IBM Statistical Packages for Social Sciences, version 29, Chicago, IL, USA). The data was presented using fundamental statistical metrics such as frequency, percentage, mean, standard deviation, and range (minimum-maximum values).

The statistical significance of differences in different percentages (qualitative data) was assessed using the Pearson Chi-square test ( $\chi^2$ -test), with the application of Yate's correction or Fisher Exact test as necessary. A significance level of 0.05 or lower was employed to establish statistical significance.

## RESULT

### Prevalence of *Acinetobacter baumannii*

From the total of 120 clinical samples collected from burn victims, 40 (33.3%) were identified as *Acinetobacter baumannii*. This high prevalence highlights the significant burden of *A. baumannii* infections in the burn units of Ramadi and Falluja Teaching Hospitals. The isolates were evenly distributed between the two hospitals, indicating a widespread issue rather than a localized outbreak.

### Demographic Distribution of *Acinetobacter baumannii* Infections.

The demographic distribution of *Acinetobacter baumannii* infections among burn patients in the two hospital units is detailed in (Table 1). This table provides a breakdown of infections by age group and gender across the two hospitals: Al-Ramadi Teaching Hospital and Falluja Teaching Hospital. These findings highlight that *A. baumannii* infections affect both genders and various age groups similarly across the two hospitals, indicating a widespread issue that is not confined to a specific demographic within these units.

Among the 40 *A. baumannii* isolates analyzed, 18 (45%) exhibited moderate biofilm formation, with 10 isolates (45.45%) from Al-Ramadi Hospital and 8 isolates (44.4%) from Falluja (Table 2).

Hospital. Strong biofilm formation was observed in 22 (55%) of the isolates, with 12 isolates (54.54%) from Al-Ramadi Hospital and 10 isolates (55.5%) from Falluja Hospital.

The statistical analysis using Pearson's chi-square test revealed no significant difference in the biofilm formation capacity of isolates from the two hospitals ( $P = 0.949$ ). This indicates that the ability of *A. baumannii* to form biofilms is consistent across isolates from both hospital units. These results highlight the pervasive capability of *A. baumannii* to form biofilms, irrespective of the hospital environment. The high proportion of strong biofilm-forming isolates underscores the challenge in



managing these infections, as biofilms contribute significantly to the resistance against antibiotics and the persistence of infections in hospital settings.

## Antibiotic Resistance Patterns

The antibiotic resistance patterns of the 40 *A. baumannii* isolates were analyzed. Out of these, 34 (85%) exhibited multidrug resistance (MDR), defined as resistance to one or more antibiotics in three or more antibiotic categories. Additionally, 6 (15%) were classified as extensively drug-resistant (XDR), meaning they were resistant to all but one or two categories of antibiotics.

### Resistance Rates:

- **Cefotaxime:** The highest resistance rate was observed for Cefotaxime, with 36 out of 40 isolates (90%) showing resistance.
- **Ciprofloxacin:** Resistance to Ciprofloxacin was also significant, with 30 isolates (75%) resistant.
- **Ampicillin/Sulbactam:** 32 isolates (80%) were resistant to ampicillin/sulbactam.
- **Piperacillin/Tazobactam:** 28 isolates (70%) showed resistance.
- **Cefepime:** Resistance was observed in 24 isolates (60%).
- **Amikacin:** 22 isolates (55%) were resistant.

Conversely, Colistin demonstrated the highest sensitivity among the isolates, with only 4 isolates (10%) showing resistance. This finding underscores the continued effectiveness of Colistin as a last-resort treatment for MDR *A. baumannii* infections (Figure 2).

## Molecular Prevalence of OXA-23, OXA<sub>48</sub>, OmpA and blaTEM Gene among carbapenem -Resistant Acinetobacter Isolates.

Out of the 40 *A. baumannii* isolates that produce carbapenem, 32 (80%) had the OXA-23 gene, 26(65%) had OmpA gene ,22 (55%) had blaTEM gene and none of the isolates had the OXA-48 gene (Figure 3and 4), respectively. The data demonstrates that the prevalence of the OXA-23 gene was higher compared to that of the OmpA,bla-TEM and OXA-48 genes.

## DISCUSSION

<sup>3</sup> In this study, we focused on *A.baumannii* bacteria infection that may isolated from burn wounds in the Al-Anbar government (Al-Ramadi Teaching Hospital Center and Al-Faluja Teaching Hospital Center) because Outbreaks resulting from <sup>43</sup> *A. baumannii* are frequent in intensive care (ICU) and burn units [18] and Patients who have sustained <sup>60</sup> burn injuries are especially vulnerable to *A. baumannii* infection while hospitalized, according to several studies. It has been reported that this bacterium ranks second in the frequency of nosocomial infections among patients who have sustained burn injuries [21].

Out of 120 patients who have burn wounds in two centers,40(33.33%) have *A.baumannii* infections; this percentage agrees with many studies performed in Iraq, which found that *A.baumannii* represents the second most frequent bacterial type isolated from the burn [21].

<sup>2</sup> *A. baumannii* has grown prevalent in hospitals due to its versatile genetic machinery, which allows it to quickly evolve resistant elements and its excellent ability to withstand demanding environments. The rising incidence of multidrug resistance <sup>2</sup> in *A. baumannii* strains has led to *A. baumannii* becoming the most significant pathogen, second only to *Pseudomonas aeruginosa*, among non-fermentative gram-negative bacteria in a burn unit [22]. The two most concerning issues are the rise of *Acinetobacter baumannii* strains <sup>2</sup> resistant to all commercially available antibiotics and the fact that new antimicrobial agents still need to be developed. As a result, there is a limited selection of antibiotics that can be used to treat *Acinetobacter baumannii* isolates that have developed resistance to multiple drugs [23]. In this study, *A.baumannii* shows 85% MDR. The proportion of MDR isolates agreed with two studies performed in Iraq [24,25], which observed that multidrug-resistant organisms were prevalent among burn injury patients in Iraq's northern regions. <sup>24</sup> Antimicrobial resistance in clinical *A. baumannii* isolates is influenced by several factors. One significant reason <sup>24</sup> is the presence of several resistance genes in MDR *A. baumannii* strains. Additionally, <sup>2</sup> horizontal gene transfer between different polyclonal MDR *A. baumannii* strains is possible [26].

<sup>75</sup> The prevalence of antibiotic resistance in *A. baumannii* is concerningly rising, resulting in heightened morbidity, mortality, and treatment expenditures within intensive care unit and burn unit environments, according to surveillance studies conducted in recent years [27]. Conversely, this

study showed that *A.baumannii* is highly sensitive to Colistin, which is in agreement with a study performed in Iran [28].

ESBLs originate from mutations that change the amino acid arrangement surrounding the active site of the narrow-spectrum beta-lactamases (TEM 1, TEM 2, or SHV 1) genes. Plasmids are easily transferable between bacterial species and are usually responsible for encoding them [29].

The identification of the blaTEM gene at the molecular level in this research may lead to resistance against cephalosporins, such as ceftazidime, cefazolin, cefoxitin, and Cefotaxime. As a result, it is accountable for the formation of phenotypic extended-spectrum  $\beta$ -lactamases [30]. Strains of *A. baumannii* produce  $\beta$ -lactamases encoded by the blaTEM gene, which are transported on plasmids and may contribute to the organism's overall longevity and long-term viability. The TEM type  $\beta$ -lactamases are derived from the enzymes TEM-1 and TEM-2. TEM-1 is a highly significant  $\beta$ -lactamase enzyme that is commonly found in Gram-negative bacteria. More than 130 TEM enzymes have been identified, utilizing a valuable mechanism to spread resistant genes [31]. In this study, 22 (55%) isolates had the blaTEM gene. The current findings disagree with Ghaima's results [32], which detected the positive blaTEM 75%.while another study by Ibrahim et al [33], reported 78.9 % of isolates carried blaTEM. On the other hand, our finding agreed with a study performed by Asgin *et al* [34], which reported 53.6% of isolates had this gene.

OmpA is a type of protein called porin, which is found in the outer membrane. The AbOmpA, a trimeric porin, plays a role in solute transport and pathogenicity in *A.baumannii* [34]. OmpA contributes to disease through many mechanisms, including apoptotic induction, immunomodulation, cell adhesion and invasion, biofilm formation, and antimicrobial resistance. AbOmpA can cause apoptosis in dendritic cells by specifically targeting the mitochondria. The clinical manifestation of *A. baumannii* infection is characterized by the overexpression of the ompA gene, which is directly linked to the development of pneumonia and bacteraemia, as well as increased patient mortality(36). In this study, 26(65%) of isolates were positive for the OmpA gene, and all 22 isolates which were strong biofilm formation showed positive OmpA this may interpret the strong relation between this gene and biofilm formation this agreement with the study performed in Iran [17] and South Korea [37] in study performed in Iraq on burn wounds 10 (80%) isolates of

*A. baumannii* were positive for OmpA this variation may be attributed to the small sample size of their study [38].

Carbapenem resistance in *A. baumannii* encompasses the development of various mechanisms, including the production of carbapenemase enzymes, alterations in membrane permeability, changes in penicillin-binding proteins, and enhanced expression of efflux pumps. *Acinetobacter* spp. commonly develop resistance to carbapenem antibiotics through the emergence of OXA-type carbapenemase and metallo- $\beta$ -lactamases (MBLs) [39]. The class D carbapenemases are a significant cause of carbapenem resistance in *Acinetobacter*. Among these, OXA-23-like and OXA-24-like carbapenemases have frequently been identified as the most common types in numerous nations [40]. Out of the 40 *A. baumannii* isolates, 32 (80%) had the bla OXA-23 gene. This percentage agrees with the many studies first performed in Pakistan [41], second in Iran [3] that found a high prevalence of the gene was 85.1% and in Tunisia [42].

The appearance of the OXA (oxacillinase) group of  $\beta$ -lactamases (Class D) has led to several challenges in managing and treating opportunistic infections. The bla<sub>OXA-48</sub> gene is highly prevalent in *K. pneumoniae* and serves multiple crucial functions, including the facilitation of biofilm formation and the development of resistance against carbapenems [43]. To date, the bla<sub>OXA-48</sub> gene has not been identified in *P. aeruginosa* isolates; only a few studies have reported OXA-48 in *A. baumannii* [39].

In this study, non-isolates had the bla<sub>OXA-48</sub> gene. These findings were in agreement with those of Cheikh et al [40], and Boral et al [44], who stated that the bla<sub>OXA-48</sub> gene was not present in any of the *A. baumannii* isolates. The bla<sub>OXA-48</sub> and bla<sub>GES-2</sub> genes were not present in any of the *A. baumannii* isolates, as reported by Romanin et al [45]. On another hand, a study in Iran showed that 92% of isolates had the bla<sub>OXA-48</sub> gene [46]. These findings indicated that the prevalence of bla<sub>OXA-48</sub> may differ among countries.

Bacterial biofilm formation is a significant pathogenicity factor that inhibits the effectiveness of antibiotics and immune defense responses [47]. *A. baumannii* has acquired numerous virulence factors and is accountable for causing severe, life-threatening infections. The capacity to create biofilms and the existence of various adhesins contribute to the emergence of infections and the



resilience to antimicrobial drugs(48).in this study, *A.baumannii*, shows the formation of biofilm in all isolates this agreement with two studies performed in Iraq [49,50].

## CONCLUSION

*Acinetobacter baumannii* remains a significant challenge in burn units due to its high rates of multidrug resistance and strong biofilm-forming ability. Effective management of *A. baumannii* infections requires a multifaceted approach, including stringent infection control measures, judicious use of antibiotics, and ongoing research into novel therapeutic strategies. The findings from this study contribute to the growing body of evidence needed to tackle this formidable pathogen and improve patient outcomes in burn units and beyond.

### Limitations of study

The study included patients from the Burn Unit of the Al-Anbar Government, which must be taken from units in all burn centers of Iraq country. Furthermore, the duration of the investigation may be short, and we suggest making the study long enough to include more samples.

### Ethical consideration

This study was approved by the Medical Ethics Committee of the University of Al-Anbar Governorate in Ramadi, Iraq, following the Helsinki Declaration. All research participants, including patients and their parents, provided signed informed consent (dated 3/12/2023).

**Disclosure:** The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article

**Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### AUTHOR'S CONTRIBUTIONS

**Noor Nadhom Khalaf:** Conceptualization, Methodology, Software, Data curation, Writing-Original draft preparation. **Mohammed Jasim Mohammed:** Visualization, Investigation. **Shaymaa Hafez Maiteb:** Supervision, Software, Validation, Writing- Reviewing and Editing,



**References:**

1. Roy S, Chowdhury G, Mukhopadhyay AK, Dutta S, Basu S. Convergence of Biofilm Formation and Antibiotic Resistance in *Acinetobacter baumannii* Infection [Internet]. Vol. 9, *Frontiers in Medicine*. 2022. Available from: <https://www.frontiersin.org/articles/10.3389/fmed.2022.793615>
2. M Al-kubaisy SH, Khalaf BH, Khaleef EL. Nosocomial infections: types and prevalence. *J Univ Anbar Pure Sci*. 2022;16(2).
3. Ranjbar R, Farahani A. Study of genetic diversity, biofilm formation, and detection of Carbapenemase, MBL, ESBL, and tetracycline resistance genes in multidrug-resistant *Acinetobacter baumannii* isolated from burn wound infections in Iran. *Antimicrob Resist Infect Control*. 2019;8:1–11.
4. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. *Acinetobacter baumannii* antibiotic resistance mechanisms. *Pathogens*. 2021;10(3):373.
5. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microb genomics*. 2019;5(10).
6. Eze EC, Chenia HY, El Zowalaty ME. *Acinetobacter baumannii* biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. *Infect Drug Resist*. 2018;2277–99.
7. Pompilio A, Scribano D, Sarshar M, Di Bonaventura G, Palamara AT, Ambrosi C. Gram-negative bacteria holding together in a biofilm: the *Acinetobacter baumannii* way. *Microorganisms*. 2021;9(7):1353.
8. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D  $\beta$ -lactamases. *Antimicrob Agents Chemother*. 2010;54(1):24–38.
9. Longo F, Vuotto C, Donelli G. Biofilm formation in *Acinetobacter baumannii*. *New Microbiol*. 2014;37(2):119–27.
10. Tawfik AF, Alswailem AM, Shibl AM, Al-Agamy MHM. Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical *Klebsiella pneumoniae* isolates from Saudi Arabia. *Microb drug Resist*. 2011;17(3):383–8.
11. Al-Ouqaili MTS, Khalaf EA, Al-Kubaisy SH. DNA Sequence Analysis of *Bla*VEB Gene Encoding Multi-drug Resistant and Extended-spectrum  $\beta$ -lactamases Producer Isolates of and. *Open Microbiol J*. 2020;14(1).
12. Gupta N, Gandham N, Jadhav S, Mishra RN. Isolation and identification of *Acinetobacter* species with special reference to antibiotic resistance. *J Nat Sci Biol Med*. 2015;6(1):159.
13. Zapata A, Ramirez-Arcos S. A comparative study of McFarland turbidity standards and the Densimat photometer to determine bacterial cell density. *Curr Microbiol*. 2015 Jun;70(6):907–9.
14. Kırmusaoğlu S. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of Agents. In: Kırmusaoğlu S, editor. Rijeka: IntechOpen; 2019. p. Ch. 6.
15. Sah RK, Dahal P, Parajuli R, Giri GR, Tuladhar E. Prevalence of *bla* CTX-M and *bla* TEM Genes in Cefotaxime-Resistant *Escherichia coli* Recovered from Tertiary Care at Central Nepal: A Descriptive Cross-Sectional Study. *Can J Infect Dis Med Microbiol*. 2024;2024.
16. Jalalvand K, Shayanfar N, Shahcheraghi F, Amini E, Mohammadpour M, Babaheidarian P. Evaluation of phenotypic and genotypic characteristics of carbapenemase-producing enterobacteriaceae and its prevalence in a referral hospital in Tehran city. *Iran J Pathol*. 2020;15(2):86.

17. Badmasti F, Siadat SD, Bouzari S, Ajdary S, Shahcheraghi F. Molecular detection of genes related to biofilm formation in multidrug-resistant *Acinetobacter baumannii* isolated from clinical settings. *J Med Microbiol.* 2015;64(Pt\_5):559–64.
18. Munier AL, Biard L, Rousseau C, Legrand M, Lafaurie M, Lomont A, et al. Incidence, risk factors, and outcome of multidrug-resistant *Acinetobacter baumannii* acquisition during an outbreak in a burns unit. *J Hosp Infect.* 2017 Nov;97(3):226–33.
19. Owlia P, Azimi L, Gholami A, Asghari B, Lari AR. ESBL- and MBL-mediated resistance in *Acinetobacter baumannii*: a global threat to burn patients. *Le Infez Med.* 2012 Sep;20(3):182–7.
20. Almasaudi SB. *Acinetobacter* spp. as nosocomial pathogens: Epidemiology and resistance features. *Saudi J Biol Sci.* 2018;25(3):586–96.
21. Abid IN. The bacteriological study of *Acinetobacter baumannii* isolated from burn patients in Al-Nasiriyah city-Iraq. *J Univesity Thi-Qar.* 2019;14(4).
22. Yang H, Liang L, Lin S, Jia S. Isolation and characterization of a virulent bacteriophage AB1 of *Acinetobacter baumannii*. *BMC Microbiol.* 2010 Apr;10:131.
23. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant *Acinetobacter baumannii* isolates producing the carbapenemase OXA-40. *Antimicrob Agents Chemother.* 2006 Sep;50(9):2941–5.
24. Ronat JB, Kakol J, Khoury MN, Berthelot M, Yun O, Brown V, et al. Highly drug-resistant pathogens implicated in burn-associated bacteremia in an Iraqi burn care unit. *PLoS One.* 2014;9(8):e101017.
25. Ghaima KK, Saadedin SMK, Jassim KA. Isolation, molecular identification and antimicrobial susceptibility of *Acinetobacter baumannii* isolated from Baghdad hospitals. *Burns.* 2015;27:31.
26. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of *Acinetobacter baumannii* endemic to New York City. *Antimicrob Agents Chemother.* 2008 Sep;52(9):2999–3005.
27. Lima WG, Silva Alves GC, Sanches C, Antunes Fernandes SO, de Paiva MC. Carbapenem-resistant *Acinetobacter baumannii* in patients with burn injury: A systematic review and meta-analysis. *Burns.* 2019 Nov;45(7):1495–508.
28. Vakili B, Fazeli H, Shoaie P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of *Acinetobacter baumannii* in Iran. *J Res Med Sci Off J Isfahan Univ Med Sci.* 2014 Mar;19(Suppl 1):S67-70.
29. Sharma J, Sharma M, Ray P. Detection of TEM & SHV genes in *Escherichia coli* & *Klebsiella pneumoniae* isolates in a tertiary care hospital from India. *Indian J Med Res.* 2010 Sep;132:332–6.
30. Shali AAK, Jalal PJ, Arif SK. Research Article Dissemination and Genetic Relatedness of Multidrug-Resistant and Extensively Drug-Resistant *Acinetobacter baumannii* Isolates from a Burn Hospital in Iraq. 2022;
31. Alkasaby NM, El Sayed Zaki M. Molecular Study of *Acinetobacter baumannii* Isolates for Metallo- $\beta$ -Lactamases and Extended-Spectrum- $\beta$ -Lactamases Genes in Intensive Care Unit, Mansoura University Hospital, Egypt. *Int J Microbiol.* 2017;2017(1):3925868.
32. Ghaima KK. Distribution of extended spectrum beta-lactamase (ESBL) genes among *Acinetobacter baumannii* isolated from burn infections. *MOJ Cell Sci Rep.* 2018;5(3):42–6.
33. Ibrahim ME, Algak TB, Abbas M, Elamin BK. Emergence of bla TEM, bla CTX-M, bla SHV and bla OXA

- genes in multidrug-resistant Enterobacteriaceae and *Acinetobacter baumannii* in Saudi Arabia. *Exp Ther Med.* 2021;22(6):1–11.
34. Asgin N, Otlu B, Cakmakliogullari EK, Celik B. High prevalence of TEM, VIM, and OXA-2 beta-lactamases and clonal diversity among *Acinetobacter baumannii* isolates in Turkey. *J Infect Dev Ctries.* 2019;13(09):794–801.
  35. Kim SA, Yoo SM, Hyun SH, Choi CH, Yang SY, Kim HJ, et al. Global gene expression patterns and induction of innate immune response in human laryngeal epithelial cells in response to *Acinetobacter baumannii* outer membrane protein A. *FEMS Immunol Med Microbiol.* 2008 Oct;54(1):45–52.
  36. Sánchez-Encinales V, Álvarez-Marín R, Pachón-Ibáñez ME, Fernández-Cuenca F, Pascual A, Garnacho-Montero J, et al. Overproduction of Outer Membrane Protein A by *Acinetobacter baumannii* as a Risk Factor for Nosocomial Pneumonia, Bacteremia, and Mortality Rate Increase. *J Infect Dis.* 2017 Mar;215(6):966–74.
  37. Aydemir H, Tuz HI, Piskin N, Celebi G, Kulah C, Kokturk F. Risk factors and clinical responses of pneumonia patients with colistin-resistant *Acinetobacter baumannii-calcoaceticus*. *World J Clin cases.* 2019 May;7(10):1111–21.
  38. Shareef SM, Risan MH. Molecular identification of *epsA* and *ompA* genes for *Acinetobacter baumannii* Isolated from Burn Wounds. *Indian J Forensic Med Toxicol.* 2021;15(2).
  39. Aruhomukama D, Najjuka CF, Kajumbula H, Okee M, Mboowa G, Sserwadda I, et al. *bla* VIM-and *bla* OXA-mediated carbapenem resistance among *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates from the Mulago hospital intensive care unit in Kampala, Uganda. *BMC Infect Dis.* 2019;19:1–8.
  40. Cheikh H Ben, Domingues S, Silveira E, Kadri Y, Rosário N, Mastouri M, et al. Molecular characterization of carbapenemases of clinical *Acinetobacter baumannii-calcoaceticus* complex isolates from a University Hospital in Tunisia. *3 Biotech.* 2018;8:1–8.
  41. Uddin F, McHugh TD, Roulston K, Platt G, Khan TA, Sohail M. Detection of carbapenemases, AmpC and ESBL genes in *Acinetobacter* isolates from ICUs by DNA microarray. *J Microbiol Methods.* 2018;155:19–23.
  42. Raddaoui A, Mabrouk A, Chebbi Y, Frigui S, Salah Abbassi M, Achour W, et al. Co-occurrence of *bla* NDM-1 and *bla* OXA-23 in carbapenemase-producing *Acinetobacter baumannii* belonging to high-risk lineages isolated from burn patients in Tunisia. *J Appl Microbiol.* 2024;135(3):1xae039.
  43. Ramos-Vivas J, Chapartegui-González I, Fernández-Martínez M, González-Rico C, Fortún J, Escudero R, et al. Biofilm formation by multidrug resistant Enterobacteriaceae strains isolated from solid organ transplant recipients. *Sci Rep.* 2019;9(1):8928.
  44. Boral B, Unaldi Ö, Ergin A, Durmaz R, Eser ÖK. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant *Acinetobacter baumannii* infections in intensive care units with clinical and environmental features. *Ann Clin Microbiol Antimicrob.* 2019;18:1–9.
  45. Romanin P, Palermo RL, Cavalini JF, Favaro L dos S, De Paula-Petroli SB, Fernandes EV, et al. Multidrug- and extensively drug-resistant *Acinetobacter baumannii* in a tertiary hospital from Brazil: the importance of carbapenemase encoding genes and epidemic clonal complexes in a 10-year study. *Microb Drug Resist.* 2019;25(9):1365–73.
  46. Tarafdar F, Jafari B, Azimi T. Evaluating the antimicrobial resistance patterns and molecular frequency of *bla*oxa-48 and *bla*GES-2 genes in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* strains isolated from burn wound infection in Tehran, Iran. *New Microbes New Infect.* 2020;37:100686.

47. Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA, Bahwerth FS. Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of *Acinetobacter baumannii* in Saudi Arabia. *Ann Clin Microbiol Antimicrob.* 2015;14:1–9.
48. Abdullah RM, Ahmed RZ. Genotype detection of *fimH* gene of *Acinetobacter baumannii* isolated from different clinical cases. *J Biotechnol Res Cent.* 2019;13(1):23–8.
49. Al-Kadmy IMS, Ali ANM, Salman IMA, Khazaal SS. Molecular characterization of *Acinetobacter baumannii* isolated from Iraqi hospital environment. *New microbes new Infect.* 2018;21:51–7.
50. Hassan PA, Khider AK. Correlation of biofilm formation and antibiotic resistance among clinical and soil isolates of *Acinetobacter baumannii* in Iraq. *Acta Microbiol Immunol Hung.* 2019;1–10.

Tables:

58

**Table 1:** The number and percentage of *A. baumannii* isolated from burn patients in two units

		Hospital Admission cite		Total	P Value
		Al-Ramadi Hospital	Al-Faluja Hospital		
Age year	21-30 n(%)	7 (31.8)	10 (55.5)	17	0.294
	31-40 n(%)	7 (31.8)	3 (16.6)	10	
	41-50 n(%)	8 (36.3)	5 (27.7)	13	
Gender	Male n(%)	10 (45.45)	7 (38.8)	17	0.676
	Female n(%)	12 (54.54)	11 (61.1)	23	

17

\*Significant difference between percentages using Pearson Chi-square test ( $X^2$ -test) at 0.05 level.

**Table 2:** The percentage of biofilm formation


Biofilm formation	Al-Ramadi Hospital	Al-Faluja Hospital	Total	P value
Moderate n(%)	10 (45.45)	8 (44.4)	18	0.949
Strong n(%)	12 (54.54)	10 (55.5)	22	

16


\*Significant difference between percentages using Pearson Chi-square test ( $X^2$ -test) at 0.05 level.




Figures:



**Figure 1:** Antibiotic susceptibility test of *A.baumannii* shows the zone of inhibition on Mueller-Hinton Agar.



**Figure 2:** Percentage of *Acinetobacter baumannii* resistance to antibiotics and multi-resistance.



**Figure 3:** Agarose gel electrophoresis represents 501 bp OXA-23 gene in Acinetobacter Species.



**Figure 4:** Show the Prevalence of <sup>57</sup>OmpA 1043bp gene in A.baumannii isolates.